FDA Gives Green Light: Clene’s New ALS Drug Moves Closer to Faster Approval
FDA may fast-track Clene’s ALS drug CNM-Au8 after strong results, offering hope for longer life and slower disease progression.
/ 181 items
#XY Event-Driven Stocks↓
“Game-Changer” Breast Cancer Drug News Triggers H.C. Wainwright Upgrade for Celcuity
Celcuity’s drug showed strong results in breast cancer, boosting survival and raising hopes it could become a new standard treatment.
FDA Approves First-Ever PROTAC Drug Veppanu for Advanced Breast Cancer with ESR1 Mutation
FDA approved Pfizer/Arvinas Veppanu pill for advanced breast cancer with ESR1 mutation, helping hormone-resistant cases.
Esperion Stock Surges 57% as ARCHIMED Acquires Company for $1.1 Billion
ARCHIMED will buy Esperion and take it private for $3.16/share (+58% premium) plus up to $100M extra payouts if targets are met.
FDA Greenlights AUVELITY: First New Treatment for Alzheimer’s Agitation in Years
FDA approves AUVELITY to treat Alzheimer’s agitation, offering a safer, effective option to reduce distress and improve patient care.
Chiesi Buys KalVista for $1.9 Billion in Biggest Deal Yet to Strengthen Rare Disease Portfolio
Chiesi will buy KalVista for $1.9B to get EKTERLY, a new oral rare disease drug, and grow its global rare disease business.